Adaptive Biotechnologies Corporation (MUN:1HM)

Germany · Delayed Price · Currency is EUR

13.88

-0.18 (-1.28%)

At close: Jan 9, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Minimal Residual Disease (MRD)	212.33M	145.53M	102.74M	87.14M	-
Minimal Residual Disease (MRD) Growth	45.90%	41.65%	17.90%	-	-
Immune Medicine	64.64M	33.43M	67.54M	98.16M	-
Immune Medicine Growth	93.38%	-50.50%	-31.20%	-	-
Biotechnology	-	-	-	-	154.34M
Biotechnology Growth	-	-	-	-	56.88%
Total	276.98M	178.96M	170.28M	185.31M	154.34M
Total Growth	54.77%	5.10%	-8.11%	20.06%	56.88%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
United States	276.98M	178.96M	170.28M	185.31M	154.34M
United States Growth	54.77%	5.10%	-8.11%	20.06%	56.88%
Total	276.98M	178.96M	170.28M	185.31M	154.34M
Total Growth	54.77%	5.10%	-8.11%	20.06%	56.88%

Source: S&P Global Market Intelligence.